CX3CL1 promotes breast cancer via transactivation of the EGF pathway

Manuel Tardáguila, Emilia Mira, Miguel A. Garcia-Cabezas, Anna M. Feijoo, Miguel Quintela-Fandino, Íñigo Azcoitia, Sergio A. Lira, Santos Mañes

1Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Darwin 3, Campus Cantoblanco, E-28049 Madrid, Spain, 2Department of Anatomic Pathology, Hospital Universitario La Paz, Pº de la Castellana, 261, E-28046 Madrid, Spain; 3Breast Cancer Unit, Clinical Research Program CNIO-Spanish National Cancer Research Center, Melchor Fernández Almagro 3, E-28029 Madrid, Spain; 4Cell Biology, Faculty of Biology, Universidad Complutense de Madrid, E-28040 Madrid, Spain, and 5Immunology Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA

Running title: CX3CL1 promotes breast cancer

Keywords: fractalkine, breast cancer, EGFR, Her-2, transactivation

*Correspondence to: Santos Mañes, Tel: (+34) 91 585-4840; Fax: (+34) 91 372-0493; e-mail: smanes@cnb.csic.es

Character count: 5,728

Authors declare no conflicts of interest
Abstract

Chemokines are relevant molecules in shaping the tumor microenvironment, although their contributions to tumorigenesis are not fully understood. We studied the influence of the chemokine CX3CL1/fractalkine in de novo breast cancer formation using HER2/neu transgenic mice. CX3CL1 expression was downmodulated in HER2/neu tumors, yet, paradoxically, adenovirus-mediated CX3CL1 expression in the tumor milieu enhanced mammary tumor numbers in a dose-dependent manner. Increased tumor multiplicity was not a consequence of CX3CL1-induced metastatic dissemination of the primary tumor, although CX3CL1 induced epithelial-to-mesenchymal transition in breast cancer cells in vitro. Instead, CX3CL1 triggered cell proliferation by induction of ErbB receptors through the proteolytic shedding of an ErbB ligand. This effect was important insofar as mammary tumorigenesis was delayed and tumor multiplicity was reduced by genetic deletion of CX3CL1 in HER2/neu mice, but not in polyoma middle T-antigen oncomice. Our findings support the conclusion that CX3CL1 acts as a positive modifier of breast cancer in concert with ErbB receptors.
Introduction

The development of most solid tumors is intimately linked to external cues provided by the microenvironment (1). Based mainly on associative studies in human cancers and tumor transplant models, a family of chemotactic proteins termed chemokines has emerged as important molecular regulators of carcinogenesis by shaping the tumor milieu. Most established human tumors produce chemokines, and their expression is associated with poor prognosis (2). The pro-tumor effects correlate with direct activity on cancer cells, as well as with the regulation of leukocyte and mesenchymal stem cell trafficking into the tumor, which create inflammatory conditions that promote progression of premalignant lesions into malignant neoplasms (2, 3). Nonetheless, specific chemokines can also exert anti-tumor effects by fostering immune responses that eliminate tumor cells (4, 5) and/or by inhibiting cell transformation and proliferation (6, 7). These paradoxical results suggest that chemokine function in tumor biology is likely to be tissue- and cell context-dependent. Moreover, the integration of chemokine cues with the complex array of other signals in the tumor environment is usually underestimated. The development of preclinical models that closely recapitulate the evolution of human malignancies would help to clarify the impact of specific chemokines on the biology of individual tumor types.

In a pilot screening for chemokine/chemokine receptor expression in various human primary cancers, we found that CX3CL1, also termed fractalkine, was downmodulated specifically in breast carcinomas compared to adjacent normal tissue (unpublished). This prompted us to study this chemokine and its receptor, CX3CR1, in more detail in breast carcinogenesis.

CX3CR1 expression is reported in different types of cancer cell lines (8, 9), including those from the breast (10), where it transduces CX3CL1-induced signals involved in phosphatidylinositol 3-kinase (PI3K)-mediated survival, proliferation and metastases. In
apparent contradiction, CX3CL1 is a transcriptional target of TP53 (11), suggesting CX3CL1/CX3CR1 involvement in tumor suppression. Moreover, forced CX3CL1 expression by tumor cells enhances NK- and CD8+ T lymphocyte-mediated anti-tumor immunity (12-14). Although these associative studies in human cancers and graft models show a role for CX3CL1/CX3CR1 in tumor biology, to our knowledge no reports have demonstrated an indispensable role for this pair in spontaneous carcinogenesis.

We addressed this question using transgenic FVB/N-Tg(MMTVneu) mice (Tg-neu), which overexpress the proto-oncogene neu (the rat erbB2 orthologue) under the control of the murine mammary tumor virus (MMTV) LTR; these Tg-neu mice develop spontaneous mammary tumors in a stepwise manner, similar to that seen in human ErbB2+ breast tumors. Increased Her2/ErbB2/Neu expression and activation is linked to the initiation and progression of human cancers, particularly in the breast (15). ErbB2 tyrosine kinase receptor (RTK) does not bind any known ligand, but amplifies signaling of other ligand-occupied receptors of the same family, Her1/ErbB1/EGFR (epidermal growth factor receptor), Her3/ErbB3 and Her4/ErbB4. There are 11 stimulatory ligands, some of which are expressed as membrane-anchored precursors, with distinct receptor specificity and affinity (16). These ligands trigger homo- and heterodimerization of ErbB receptors, leading to tyrosine phosphorylation and signal transduction; heterodimerization even enables signaling of the kinase-defective receptor ErbB3.

ErbB receptors can be modulated indirectly by a broad set of heterologous receptors in response to environmental conditions. Cytokine receptors, voltage-gated Ca2+ channels, integrins, G protein-coupled receptors (GPCR) and Wnt signals induce ErbB receptor transactivation (17, 18). In some cases, this crosstalk involves direct transphosphorylation by intracellular tyrosine or serine/threonine kinases, causing ErbB receptor activation or endocytosis, respectively (19, 20). In many cases, the crosstalk involves cleavage of a
transmembrane EGF-like precursor, which then activates the receptor in a paracrine/autocrine manner (18, 21); this appears to be the mechanism by which CX3CL1 induces ErbB1 transactivation in smooth muscle cells (22). Transactivation of ErbB receptors could contribute to cancer by integrating distinct signals in the tumor milieu (17).

Using gain- and loss-of-function approaches, we provide genetic evidence that supports a role for CX3CL1 in mammary carcinoma promotion in Tg-neu mice. CX3CL1 transactivates ErbB receptors in human breast cancer cells and Tg-neu mouse primary mammary gland cultures, leading to the induction of the ERK pathway and cell proliferation. In contrast, CX3CL1 does not influence mammary carcinogenesis in Tg-PyMT mice, in which the ERK signaling pathway is constitutively activated by the mouse polyoma virus middle T-antigen (PyMT) oncogene. We thus propose that CX3CL1 acts as a specific tumor promoter for ErbB2-expressing mammary carcinomas.
Materials & Methods

Mouse and human samples. Transgenic FVB/N-Tg(MMTV-neu)202Mul/J mice and transgenic MMTV-polyoma middle T-antigen (FVB/N-Tg(MMTV-PyVT)634Mul/J) mice were from Jackson Laboratory. C57BL/6 CX3CL1<sup>−/−</sup> mice (23) were backcrossed for more than 10 generations to the FVB background while maintaining CX3CL1 in heterozygosis. CX3CL1<sup>+/+</sup> (WT), CX3CL1<sup>+/−</sup> and CX3CL1<sup>−/−</sup> littermates on Tg-neu or Tg-PyMT backgrounds were generated after crossing appropriate heterozygous mice, and were monitored weekly for mammary tumors from age 20 (neu) or 4 weeks (PyMT). When detected, tumors were measured weekly with calipers and volume calculated (24). Live animal experiments were supervised by the Centro Nacional de Biotecnología Ethics Committee according to national and European Union guidelines.

To study for human breast tumors, we used four samples (two intraductal and two invasive breast carcinomas), obtained from the Spanish Centro Nacional de Investigaciones Oncológicas (CNIO) Tumor Biobank, a national network with anonymized patient data that coordinates the main hospitals in Spain. Institutional ethics boards approved sample transfer to local biobanks with patient consent. All four cases (all HER-2-positive) derived from primary breast surgery for suspicion of malignancy based on radiological findings.

Cell lines. MCF-10A, T47D, MCF-7, BT-474, MDA-MB-468, Hs-578T, and MDA-MB-231 were from the ATCC. Murine N202.1A and 1g11 cell lines were kind gifts of V. Bronte (Verona University, Verona, Italy) and A. Mantovani (Inst. Humanitas, Milan, Italy), respectively. Cells were cultured in distinct media (Supplementary Table S1) supplemented with 2 mM glutamine and 100U/ml each penicillin and streptomycin. MDA-MB-468 cells were cultured at 37°C in air without supplementary CO₂.

Isolation of cell subpopulations from mammary glands and tumors. Mammary glands were extracted from Tg-neu mice (8- to 12-week-old) after removal of inguinal lymph nodes.
For mammary tumors, a single tumor mass was used in each experiment. Glands and tumors were digested (16 h, 37°C) in DMEM/F12 (1:1) with 300 U/ml collagenase/100 U/ml hyaluronidase (Stem Cell Technologies) and gentamicin (50 μg/ml). Digestion was terminated by addition of HBSS (Gibco) with 10 mM HEPES and 2% FCS, and single cell suspensions obtained (25). CD45<sup>+</sup> and TER119<sup>+</sup> cells were depleted by sequential incubation with anti-CD45 (clone 30-F11) and -TER119 (TER119; BD Biosciences), followed by sheep-anti-rat-coated magnetic beads (Invitrogen). Remaining cells were stained with anti-CD31-PE (MEC 13.3) and -CD24-FITC (M1/69; BD Biosciences) antibodies and sorted by FACS (Beckman Coulter). Isolated fractions were lysed immediately with TRI Reagent (Sigma) and stored (-80°C) for RNA extraction. Samples of each isolation stage were stained with the violet Live/Dead Cell stain kit (Invitrogen) and anti-CD45-FITC (I3/2.3), CD31-PE and CD24-PE-Cy5 (BD Biosciences).

**Quantitative PCR.** Murine and human CX3CR1 and CX3CL1 were quantified by real-time qPCR (RT-qPCR), using the primers listed in Supplementary Table S2, in an ABI PRISM 7900 HT using Sybr Green-based reaction mix (Euroclone) and β-actin to normalize data. The first cDNA strand was synthesized from total RNA (usually 1 μg) with the High-Capacity cDNA Archive kit (Applied Biosystems) using random octamers as primers. Melting curve analyses were performed to validate generation of the specific PCR product.

**CX3CL1 ELISA.** CX3CL1 concentration was measured in extracts, serum or culture supernatants with Human or Mouse CX3CL1 DuoSet ELISA (R&D Systems), with plates coated with capture antibody (4°C, overnight). Breast tumors or glands were dissected from Tg-neu mice, pulverized in liquid N<sub>2</sub>, and the powder homogenized in RIPA buffer with protease and phosphatase inhibitors. Protein in cleared homogenate (20,000 x g, 30 min) was quantified (micro-BCA Protein Assay Kit, Pierce) and aliquoted (-80°C). Different amounts of total protein were assayed in triplicate for each sample; non-specific signal was determined.
in each experiment by assaying an extract from pooled mammary glands of CX3CL1−/− mice, and subtracted from each sample value. Human and mouse cell lines were lysed in RIPA buffer and extracts assayed as above.

**Adenoviral gene therapy.** The AdEasy Adenoviral Vector System (Stratagene) was used throughout. Murine CX3CL1 cDNA was amplified and cloned into the shuttle pCMV vector. High titer stock of Ad-CX3CL1 and Ad-LacZ were prepared by the Unidad de Producción de Vectores (Centro de Biotecnología Animal y Terapia Génica, Barcelona, Spain). Ad-CX3CL1 and Ad-LacZ virus activity was analyzed by infection of N202.1A and 1g11 cells in solution; CX3CL1 levels and β-galactosidase activity were measured after 72 h. For mouse studies, Ad-CX3CL1 or Ad-LacZ viruses (5 × 10^8 infectious particles/40 μl) were injected into Tg-neu mouse tumors (75-150 mm³) at a single dose or in six doses (two per week). Injected tumors were measured weekly and mice monitored for new lumps. Histopathological analyses were performed on hematoxylin/eosin-stained sections of tumors, healthy mammary glands, and axillary, cervical and inguinal lymph nodes of treated mice; several representative sections of each sample were analyzed.

**Epithelial-to-mesenchymal transition (EMT) assays.** CX3CL1-induced expression of snail-1, snail-2, twist-1 and cdh1 (E-cadherin) genes was studied in Ad-CX3CL1- and Ad-LacZ-infected (100 m.o.i.) T47D cells (80-90% confluence) by RT-qPCR using specific primers (26). In some cases, T47D-infected cells (48 h post-infection) were treated (24 h, 37ºC) with PTx (750 ng/ml, Sigma) or vehicle.

For subcellular E-cadherin location studies, T47D cells were seeded on fibronectin-coated slides, pretreated (8 h, 37ºC) with PBS or CX3CL1 antagonist (R&D Systems), and stimulated with CX3CL1 (11 nM; 24 h, 37ºC). Cells were fixed (4% paraformaldehyde), permeabilized (0.1% Triton X-100) and stained sequentially with anti-E-cadherin (Sigma) and Alexa488-anti-mouse antibody (Jackson ImmunoResearch). Samples were mounted in...
Vectashield/DAPI medium (Vector Laboratories); images were acquired with a LSM 510 Meta confocal microscope (Zeiss) and processed with ImageJ.

Cell migration was assayed in vitronectin-coated (5 μg/ml, 20 h, 4°C; BD Biosciences) Transwell chambers (8μm pore; Costar). T47D cells were pretreated (24 h) with CX3CL1 (30 nM) in RPMI with 0.1% BSA (RPMI-BSA), washed extensively, and seeded (10^5 cells) in the upper chamber; lower chambers were filled with RPMI-BSA alone or with 1% FCS, CX3CL1, or both. After incubation (18 h, 37°C), cells on the upper side of the membrane were removed with a cotton swab, and cells on the underside were fixed and stained (Grifols Staining Solution, Spain). Cells were counted in six different high-power fields in triplicate wells, in two independent experiments.

[^3H]-thymidine incorporation assays. T47D cells (10^4/well) were pretreated (1 h, 37°C) with MMP inhibitors AG1478 or GM6001 (both at 1 μM), stimulated with CX3CL1 (60 nM; 36 h), and pulsed with methyl[^3H]-thymidine ([^3H]-TdR, 1 μCi/well, 12 h; Perkin Elmer). Nuclei were harvested using a MicroBeta TriLux workstation and[^3H]-TdR incorporation was determined on a liquid scintillation counter (Perkin Elmer).

CX3CL1-induced signaling. Serum-starved (48 h) T47D cells were pretreated with PTx (750 ng/ml, 16 h), AG1478 (1 μM, 1 h; Calbiochem) or GM6001 (1 μM, 1 h; Chemicon) and stimulated with CX3CL1 (30 nM) or EGF (10 ng/ml) for indicated times. Cells were lysed in ice-cold 20 mM Tris-HCl pH 7.0, 140 mM NaCl, 50 mM EDTA, 1% glycerol, 1% NP-40, with protease and phosphatase inhibitors. Protein lysates (20 μg) were resolved in SDS-PAGE and blotted with polyclonal antibodies to the unphosphorylated and phosphorylated forms of extracellular regulated kinases (ERK-1/2) and AKT (Cell Signaling Technology). Blots were stripped in Reblot Plus Strong Solution (15 min, 20°C; Millipore). In blocking experiments, T47D cells were pretreated (10 min, 37°C) with neutralizing antibodies (20 μg/ml; R&D Systems) to human amphiregulin (MAB262), HB-EGF (AF-259), transforming growth factor
(TGF)α (AF-239), or nonspecific IgG, before stimulation with CX3CL1 (as above) or appropriate ligands.

For immunoprecipitation, cells were lysed in ice-cold Tris buffer as above but containing 0.5% NP-40, and further disrupted by sonication. Cell lysates (0.5 mg) were pre-cleared with goat anti-mouse IgG antibody coupled to agarose beads (Sigma) before incubation (1 h, 4°C) with agarose-coupled anti-phosphotyrosine (pTyr) monoclonal antibody (clone PY69; BD Biosciences). Immunoprecipitates were assayed by western blot with anti-EGFR (D38B1) and -HER-2 (29D8) antibodies (Cell Signaling Technology).

Calcium mobilization assays were performed as described (27). Serum-starved (48 h) T47D cells, untreated or pretreated with PTx (750 ng/ml), were loaded with Fluo-3,AM (300 mM, 20 min, 37°C; Molecular Probes). Cells were pre-warmed in RPMI-BSA with 2 mM CaCl₂ before CX3CL1 stimulation (60 nM). Ca²⁺ release was determined (37°C, 525 nm) in an EPICS XL cytometer (Beckman Coulter).

For primary cultures, CD45- and Ter119-depleted cell suspensions were cultured (20 h) in EpiCult-B (Stem Cell Technologies) with 5% FCS and gentamicin, followed by starvation in DMEM:F12 (1:1) with 0.5% FCS (4 h), and then stimulated with recombinant murine CX3CL1 (200 nM; R&D Systems). Cell extracts were assayed by western blot with polyclonal anti-pErbB2 (Upstate Biotechnology) and -HER-2 (29D8).

**Immunohistochemistry.** CX3CL1 was analyzed in cryosections of mouse mammary glands, blocked with 10% BSA in PBS (2 h, 20°C), followed by incubation (16 h, 4°C) with anti-CX3CL1 antibodies AF537 (2 μg/ml) or MAB571 (1.1 μg/ml; both from R&D Systems), or sc-7227 (8 μg/ml; Santa Cruz Biotechnology). After incubation with appropriate secondary antibodies (1 h, 20°C), samples were mounted and observed under a fluorescence microscope (Leica). CX3CR1 was analyzed in mammary tumors and glands using a recombinant hFc-CX3CL1 prepared in our laboratory, followed by biotin-rat anti-hFc antibody and Cy3-
streptavidin. Paraffin-embedded human breast carcinomas were stained with the anti-CX3CL1 antibody AF365 (R&D Systems; 15 μg/ml, 14 h, 4ºC) in PBS containing 1.5% rabbit serum. After incubation with a biotin-labeled rabbit anti-goat antibody (1 h, 20ºC) and amplification with the ABC method (Thermo Sci), the signal was developed with 3-amino-9-ethylcarbazole (AEC, Sigma-Aldrich). Sections were hematoxylin-counterstained.

**Statistical methods.** Significant differences were identified by Student’s *t* test, Mann-Whitney test, one-way ANOVA with Dunnett post-test, two-way ANOVA with Bonferroni post-test, and a Fisher two-tailed test, as indicated. Data are expressed as mean ± SEM.
Results

CX3CL1/CX3CR1 are expressed in the mammary gland

Although CX3CL1/CX3CR1 are implicated in oncogenesis in several tissues, the expression and function of this pair in spontaneous carcinogenesis has not been analyzed. We combined magnetic isolation and flow cytometry to analyze CX3CL1 mRNA expression in cell subpopulations from mammary glands before tumor onset in Tg-neu mice. Five major cell populations were isolated based on three markers, CD45 (leukocytes), CD31 (endothelial cells), and CD24, which distinguishes luminal epithelial cells (CD24\textsuperscript{high}), basal/myoepithelial cells (CD24\textsuperscript{med}) and a mixed CD24\textsuperscript{low/-} population composed of fibroblasts, adipocytes and neurons (25, 28). A representative isolation experiment is shown (Fig. 1A), as well as the relative proportion of each cell type in mammary gland (Fig. 1B). Endothelial and epithelial cells expressed CX3CL1 mRNA; in epithelial cells, expression was higher in luminal (CD24\textsuperscript{high}) than in basal/myoepithelial cells (CD24\textsuperscript{med}) (Fig. 1C). Hematopoietic cells showed no CX3CL1 mRNA, but expressed the highest levels of its receptor, CX3CR1, compared to endothelial and luminal epithelial cells (Fig. 1C, D). CX3CR1 mRNA was undetectable in CD24\textsuperscript{med} and CD24\textsuperscript{low/-} cells. Attempts to visualize CX3CL1 by immunohistochemistry in mammary glands of nulliparous Tg-neu mice before tumor onset were unsuccessful, as three commercial antibodies yielded similar erratic staining in mammary tissue from wild type and CX3CL1\textsuperscript{-/-} mice (Supplementary Fig. S1).

CX3CL1 is downmodulated in breast tumors

We tested CX3CL1/CX3CR1 expression after mammary tumor onset. Most cells isolated from these tumors were CD24\textsuperscript{high}, which is consistent with the luminal origin of Tg-neu mammary carcinomas; some endothelial and hematopoietic cells also infiltrated these tumors (Fig. 2A). Only endothelial and luminal epithelial cells expressed CX3CL1. CX3CL1 mRNA levels were significantly downmodulated in CD24\textsuperscript{high} tumor cells compared to untransformed
cells (Fig. 2B); CX3CL1 mRNA was also slightly reduced in endothelial cells isolated from tumors relative to normal tissue. CX3CL1 protein levels were lower in total extracts from tumors vs. normal mammary tissue (Fig. 2C); paired analysis of CX3CL1 levels in tumors and healthy mammary glands from the same mice confirmed CX3CL1 downmodulation in carcinomas (Fig. 2D).

In contrast, CX3CR1 mRNA was upregulated in specific cell populations isolated from tumors; this increase was significant in CD24\textsuperscript{high} and CD45\textsuperscript{+} cells, but receptor expression was unaffected in endothelial cells (Fig. 2E). Fc-CX3CL1 staining showed CX3CR1 expression in tumors and in normal mammary tissue (Supplementary Fig. S2); differences in staining intensity between the two tissues were not evident, as would be predicted by mRNA data.

We analyzed CX3CL1 and CX3CR1 regulation in human breast tumors. Analysis of public data (GEOprofile Database GSE3744, GDS3324; EMBL-EBI Database GEOD10780) from three independent studies (29-31) showed downregulation of CX3CL1 expression in human primary breast tumors compared to healthy breast tissue (Fig. 2F). The results for CX3CR1 were not conclusive, since only two of these studies showed a significant reduction in CX3CR1 mRNA in tumor samples (Fig. 2F). CX3CL1 staining was lower in a small set of \textit{in situ} and invasive human breast ductal carcinomas compared to non-tumor tissue from the same patient (Fig. 2G, H). Downmodulation of CX3CL1 expression in Tg-neu tumors might thus be a broad phenomenon in human breast cancer.

**CX3CL1 overexpression increases tumor number in Tg-neu mice**

Given the anti-tumor activity of CX3CL1 in some cancer models (12-14, 32), its downregulation in Tg-neu tumors could be the result of a selection mechanism that silences a potential anti-oncogenic factor. CX3CL1 is produced as a membrane-anchored protein that can be cleaved by specific matrix metalloproteases (MMP); tethered and shed CX3CL1 forms
can have different functions (33, 34). To assess the result of enhanced CX3CL1 expression in the tumor environment, we inoculated Tg-neu mice intratumorally (i.t.) with recombinant adenoviruses to express the full-length (membrane-tethered) CX3CL1 (Ad-CX3CL1) or β-galactosidase (Ad-LacZ). These adenoviruses infected the N202.1A murine mammary cancer cell line (Fig. 3A, B) and the 1g11 mouse endothelial cell line (Fig. 3C, D), as determined by dose-dependent expression of CX3CL1 mRNA and protein; β-galactosidase activity was also detected in extracts of Ad-LacZ-infected N202.1A cells (Fig. 3B). These adenoviruses thus transduce the cx3cl1 gene in various cell types in the tumor parenchyma.

As soon as Tg-neu mice presented a palpable lump (75-150 mm³), they received six i.t. injections of Ad-CX3CL1 or Ad-LacZ. As predicted, Ad-CX3CL1 i.t. injection increased CX3CL1 mRNA levels in tumor (CD24⁺) and endothelial (CD31⁺) cells (Fig. 3E), as well as serum CX3CL1 levels (Fig. 3F) compared to those in Ad-LacZ-injected mice. Primary tumors that received injections of Ad-CX3CL1 and Ad-LacZ had similar growth kinetics (Fig. 3G), and showed no relevant differences in morphology, malignancy score or mitotic figures (Fig. 3H, I); the tumors were non-infiltrating. Proliferation and apoptosis rates, determined by phospho-histone H3 and TUNEL staining, respectively, were also comparable for Ad-LacZ- and Ad-CX3CL1-treated tumors (Supplementary Fig. S3A, B). There were no apparent differences in the angiogenic pattern between the two tumor groups (Supplementary Fig. S3C).

Ad-CX3CL1-treated mice showed a significant increase in the number of mammary glands with palpable tumors compared to those treated with Ad-LacZ (Fig. 3J). Moreover, mammary glands from treated mice with no macroscopically detectable tumors exhibited microscopic tumors composed of epithelial cells with moderate atypia and some mitoses (Fig. 4A, B); these masses did not invade the surrounding stroma and showed no sign of necrosis. Some acini and ductuli near these tumors had normal structure (Fig. 4C), whereas
others showed proliferation towards the lumen of epithelial cells with mild atypia (Fig. 4D); hyperplastic foci were not always found in the vicinity of tumors (Fig. 4E). These microscopic tumors were more abundant in Ad-CX3CL1- than in Ad-LacZ-injected mice; of six mammary glands analyzed in each case, we detected five foci in Ad-CX3CL1- and two in Ad-LacZ-treated mice. To analyze whether differences in tumor multiplicity between adenoviruses were due to a LacZ-induced immune response, CD4+ or CD8+ T cells were isolated from lymph nodes and spleen of Ad-CX3CL1- (control) and Ad-LacZ-injected mice, and incubated ex vivo with syngeneic, γ-irradiated splenocytes loaded with 50, 5 or 0.5 μg of LacZ. Proliferation of T cells from Ad-LacZ- or Ad-CX3CL1-injected mice showed no differences at any antigen dose tested (not shown), suggesting that repeated i.t. Ad-LacZ injection did not induce a specific T cell response in our mice.

We also observed a tendency toward increased multiplicity of palpable tumors in mice that received a single i.t. dose of Ad-CX3CL1, although tumor growth kinetics were unaffected (Supplementary Fig. S4). Elevation of CX3CL1 levels in the tumor environment appears to promote mammary carcinogenesis in Tg-neu mice in a manner dependent on dose and/or duration of exposure.

**Lack of lymph node metastases in Ad-CX3CL1-injected mice**

Since CX3CL1 can induce metastasis in some models (8, 9), the Ad-CX3CL1-induced increase in tumor multiplicity could be a result of neoplastic cell dissemination due to chemokine overexpression. Analysis of a collection of human breast cancer cell subtypes with distinct metastatic capacity (35) showed no apparent correlation between CX3CL1 or CX3CR1 mRNA (Supplementary Fig. S5) or protein expression (Supplementary Fig. S6) and the invasive/metastatic potential of the cell lines tested; the untransformed breast epithelial cell line MCF-10A was used as a reference. We also tested whether CX3CL1 could induce epithelia-to-mesenchymal transition (EMT) in breast cancer cells, since EMT is proposed as a
central step in breast cancer dissemination (36, 37). T47D cells, which express CX3CR1 but not its ligand, were infected with Ad-CX3CL1 and Ad-LacZ. Ad-CX3CL1-infected cells showed significantly upregulated mRNA levels of the EMT master gene snail2 (formerly slug) compared to Ad-LacZ-infected cells (Supplementary Fig. S7A). Increased snail2 expression in Ad-CX3CL1 cells was pertussis toxin (PTx)-sensitive (Supplementary Fig. S7B), indicating that this upregulation was Gαi-mediated. Moreover, CX3CL1 stimulation delocalized E-cadherin from intercellular membranes of T47D cells; this phenotype was partially reversed by co-incubation of CX3CL1 with the N-terminal truncated antagonist CX3CL129-102 (Supplementary Fig. S7C-E). CX3CL1-induced delocalization of intercellular E-cadherin correlated with the dose-dependent effect of CX3CL1 in boosting serum-induced T47D cell migration (Supplementary Fig. S7F). The lymphatic vessels are most common route of initial tumor cell dissemination in vivo (38). Although CX3CL1 induced EMT and enhanced cancer cell motility in vitro, we found no tumor cells in axillary, cervical or inguinal lymph nodes from Ad-CX3CL1- (n = 24) or Ad-LacZ-injected mice (n = 18; Supplementary Fig. S8). We detect no tumor cells in blood or metastases in lung.

**CX3CL1 induces transactivation of the EGF pathway**

An alternative explanation for the increased tumor multiplicity in Ad-CX3CL1-injected mice is the CX3CL1 potential to stimulate tumor cell expansion, which we studied using T47D cells. [³H]-TdR incorporation assays showed that CX3CL1 alone was a weak mitogen; nevertheless, it enhanced cell proliferation in the presence of FCS (Fig. 5A). CX3CL1-induced T47D cell proliferation was inhibited by treatment with AG1478, an inhibitor of ErbB1 kinase activity, or the broad-spectrum MMP inhibitor GM6001 (Fig. 5A). These results suggested that CX3CL1-induced T47D cell proliferation involves transactivation of ErbB receptors through MMP-dependent shedding of a transmembrane ligand precursor of the epidermal growth factor (EGF) axis, as reported for other cell types (22)
To obtain direct evidence that CX3CL1 activates the EGF pathway, we analyzed tyrosine phosphorylation of ErbB receptors in CX3CL1-stimulated T47D cells. These cells express ErbB receptor levels comparable to those in normal breast tissue and do not show ErbB2 amplification (not shown). In this model, CX3CL1 induced ErbB1 phosphorylation, which peaked at 10-30 min post-stimulation (Fig. 5B); AG1478 abrogated CX3CL1-induced ErbB1 phosphorylation, indicating that it required the ErbB1 kinase activity (Fig. 5B).

We then tested the dependence of CX3CL1-triggered signaling pathways on ErbB transactivation. PTx treatment inhibited CX3CL1-mediated Ca^{2+} flux (Fig. 5C), implicating a Gi protein in this process. In contrast, CX3CL1-induced ERK1/2 phosphorylation was unaffected by PTx, but was significantly reduced after GM6001 or AG1478 treatment (Fig. 5D; Supplementary Fig. S9A), suggesting the importance of CX3CL1/ErbB crosstalk in the activation of the mitogenic ERK pathway. Neither PTx nor the MMP inhibitors GM6001 or BB94 inhibited AKT phosphorylation (Fig. 5E; Supplementary Fig. S9B), implying that it is independent of ErbB transactivation. It should be noted that T47D cells have mutations in the PI3K pathway (39).

T47D cells express several membrane-bound EGF family ligands (Supplementary Fig. S10). To determine which of these ligands is involved in CX3CL1/ErbB crosstalk, T47D cells were stimulated with CX3CL1 in the presence of neutralizing antibodies to amphiregulin, HB-EGF, or TGFRa. Each of these antibodies partially inhibited CX3CL1-induced ERK1/2 phosphorylation (Fig. 5F), suggesting that multiple ErbB ligands are involved in the transactivation circuit.

To determine whether CX3CL1-induced ErbB activation occurs in primary Tg-neu tumors, we stimulated cells from spontaneous carcinomas with CX3CL1, alone or with GM6001 to prevent proteolysis of EGF precursors; phosphorylated ErbB2 levels were then analyzed in total cell extracts. CX3CL1 stimulation of primary tumor cells induced only a
slight increase in ErbB2 phosphorylation, which was not inhibited by GM6001 (Fig. 5G), possibly due to constitutive ErbB2 phosphorylation in the Tg-neu model (Fig. 5G and (40)). We therefore analyzed CX3CL1/ErbB crosstalk in primary mammary epithelium, before transforming ErbB2 mutations occurred. CX3CL1 stimulation of these cultures induced a clear increase in ErbB2 phosphorylation, which was inhibited by GM6001 addition (Fig. 5H). These data thus indicated that CX3CL1 triggers ErbB2 transactivation in the preneoplastic mammary epithelium of Tg-neu mice.

**CX3CL1 deficiency delays mammary tumor onset in Tg-neu mice**

One implication of these results is that CX3CL1 deficiency would affect mammary tumorigenesis in Tg-neu mice. We crossed C57BL/6-CX3CL1<sup>+/−</sup> with Tg-neu mice; as C57BL/6-FVB/N-Tg(MMTVneu)-CX3CL1<sup>+/−</sup> mice were extremely resistant to mammary cancer (not shown), we backcrossed mice for more than 10 generations on the FVB background. Although C57BL/6-CX3CL1<sup>+/−</sup> mice show no overt phenotype (23), ~60% of FVB-Tg-neu-CX3CL1<sup>+/−</sup> mice died of causes that remain to be identified; death was not sex-associated. CX3CL1 deficiency did not compromise mammary gland development or architecture, as suggested by the lack of lactation problems in the surviving Tg-neu-CX3CL1<sup>+/−</sup> mice and the lack of differences in the structure and cell types composing the mammary gland of mature Tg-neu-CX3CL1<sup>+/−</sup> compared to WT mice (Supplementary Fig. S11).

Analysis of nulliparous Tg-neu-CX3CL1<sup>+/−</sup> mice showed a significant delay in mammary tumor onset (Fig. 6A) and decreased tumor multiplicity (Fig. 6B) compared to WT mice. Approximately 30% of Tg-neu-CX3CL1<sup>+/−</sup> females had not developed tumors by 15 months of age. Tg-neu-CX3CL1<sup>+/−</sup> mice also showed a significant delay in tumor onset (Fig. 6A) and a decrease in tumor multiplicity (Fig. 6B) compared to WT controls. It should be noted that CX3CL1 expression was hemizygous in Tg-neu-CX3CL1<sup>+/−</sup> mouse mammary tissue and
tumors (Supplementary Fig. S12). Tumors in all three genotypes showed no differences in growth kinetics (Fig. 6C), again suggesting CX3CL1 involvement only at early stages of mammary carcinogenesis.

The delayed onset and reduced number of mammary tumors in CX3CL1-deficient and hemizygous mice might be linked to the crosstalk between this chemokine and ErbB2. FVB-Tg(MMTV-PyMT) (Tg-PyMT) mice develop multifocal, aggressive polyclonal tumors at 7-8 weeks of age, due to polyoma middle T-antigen (PyMT) activation of a number of signaling molecules, many of which are shared with ErbB2 (41). We generated CX3CL1-deficient Tg-PyMT mice; Tg-PyMT-CX3CL1\(-/-\), -CX3CL1\(+/-\) and WT mice showed no difference in tumor onset (Fig. 6D) or in mean tumor number per mouse (Fig. 6E). Tumor growth kinetics was similar for Tg-PyMT-CX3CL1\(+/-\) and WT mice, with a slight reduction in Tg-PyMT-CX3CL1\(-/-\) mice at late stages (Fig. 6F). These results suggest that the mammary carcinogenesis inhibition associated to reduced CX3CL1 levels depends on ErbB2 overexpression.
Discussion

Several \textit{in vitro} and transplantable tumor model studies have analyzed the influence of the CX3CL1/CX3CR1 pair in the biology of tumor cells and the possible utility of targeting CX3CL1 for immunotherapy. Here we studied CX3CL1 and CX3CR1 expression in the mammary gland and in spontaneous mammary carcinogenesis.

In Tg-neu mice, mammary tumors showed increased CX3CR1 and decreased CX3CL1 mRNA levels compared to healthy tissue. Despite CX3CL1 downregulation in established tumors, our data suggest that CX3CL1 is a tumor promoter in Tg-neu mice. Two lines of evidence support this hypothesis. First, ectopic CX3CL1 expression by Ad-CX3CL1 injection increased tumor multiplicity, although it did not affect tumor growth kinetics. In \textit{in vitro} studies, Ad-CX3CL1 elicited changes in gene expression reminiscent of EMT in T47D breast cancer cells, and potentiated migration of these cells, suggesting a "permissive" role for CX3CL1 in cancer cell motility, as described for CCL5 (42). \textit{In vivo} results nonetheless indicated that Ad-CX3CL1 did not induce metastases. The absence of lymph node and macroscopic pulmonary metastases, and the preservation of basal lamina integrity in the microscopic tumors detected in Ad-CX3CL1-treated mice, indicate that Ad-CX3CL1 fosters development of neoplastic lesions rather than metastatic dissemination of the injected tumor. This idea is reinforced by the dose-dependent effect of Ad-CX3CL1 treatment on tumor multiplicity. Damage to the tumor vasculature during injection could facilitate systemic virus dissemination (43), enabling the infection of distal mammary glands. In addition, CX3CL1 can be cleaved from the membrane of Ad-CX3CL1-transduced cells, leading to increased serum CX3CL1 levels.

The second line of evidence is the significant delay in the onset of spontaneous mammary tumors and the reduction in tumor multiplicity in Tg-neu-CX3CL1\textsuperscript{−/−} and hemizygous Tg-neu-CX3CL1\textsuperscript{+/−} mice compared to WT littermates. The growth kinetics of established tumors was
nonetheless unaffected by CX3CL1 deficiency, which concurs with the lack of Ad-CX3CL1 effect on tumor growth. These data suggest that in this model, CX3CL1 promoter activity takes place in early stages of carcinogenesis.

Tumor multiplicity is not comparable between Ad-LacZ-injected (Fig. 3J) and non-injected Tg-neu mice (Fig. 6B); this could be a consequence of an injury reaction due to repeated intratumor injection of adenovirus. Such a response could re activates a low-affinity, neu-specific T cell repertoire in Tg-neu mice (24), thus partially restricting tumor growth. This reaction, which would be similar in Ad-LacZ- and Ad-CX3CL1-injected mice, would not occur in non-injected Tg-neu mice.

The mechanism by which CX3CL1 enhances mammary carcinogenesis in Tg-neu mice is not entirely clear. Although CX3CL1 is a proinflammatory chemokine that might promote tumorigenesis by fostering inflammation, histological analyses showed no marked changes in the inflammatory infiltrate associated with CX3CL1 overexpression or deficiency in Tg-neu tumors. Our in vitro results using human breast cancer lines and primary mammary epithelial cells from Tg-neu mice indicate that CX3CL1 enhances cell proliferation by transactivating ErbB receptors. Moreover, CX3CL1 deficiency does not affect tumor onset or multiplicity in Tg-PyMT mice, thus associating CX3CL1-mediated stimulation of mammary carcinogenesis with ErbB2 overexpression and signaling. CX3CR1-ErbB crosstalk is probably not involved in tumor initiation; most mammary tumors in Tg-neu mice have in-frame deletions and insertions of cysteine residues in the ErbB2 extracellular domain, which leads to constitutive receptor dimerization and activation (40).

Accumulated evidence indicates bidirectional cross-communication between GPCR, the family to which CX3CR1 belongs, and RTK such as ErbB receptors (18, 21, 42). Although this crosstalk might take place exclusively through intracellular signaling circuits, GPCR usually induce RTK transactivation through an extracellular mechanism involving proteolytic
release of the RTK ligand, which binds to and activates the receptor (17, 18). This "triple passing membrane" signaling usually leads to MAPK pathway activation (18). The blockade of CX3CL1-mediated cell proliferation and of ERK activation in T47D cells by a general MMP inhibitor indicates that CX3CL1/ErbB crosstalk is controlled by ErbB ligand release from the cell membrane. The specific ligand involved in the transactivation circuit might depend on cell type; for instance, blockade of HB-EGF, amphiregulin, or TGFα inhibited CX3CL1-induced ERK activation in T47D cells.

Analysis of CX3CL1-triggered signaling pathways in breast tumors suggested that ErbB transactivation was specifically needed for CX3CL1-mediated ERK activation, which was unaffected by PTx, but was impaired by the general MMP inhibitor. The ERK pathway induces transcription and secretion of several ErbB ligands (44), which could create a positive feedback loop that fosters tumor progression. In contrast to ERK, PI3K pathway activation was MMP-independent, suggesting that ErbB transactivation was not involved. In addition, PTx did not inhibit AKT phosphorylation, implying that PI3K activation is Gαi-independent in T47D cells. In smooth muscle cells, CX3CL1-induced ErbB transactivation is implicated in PI3K, but not in ERK activation (22).

We thus propose a model in which CX3CL1 accelerates the development of incipient neoplastic lesions by enhancing the ERK pathway through ErbB transactivation (Fig. 7). Such crosstalk would not operate in Tg-PyMT mice, since membrane-bound PyMT directly triggers PI3K and ERK signaling pathways after c-SRC binding and activation (45); this would render PyMT-expressing cells independent of CX3CL1 and ErbB, although PyMT can induce ErbB2 upregulation. The CX3CL1/ErbB crosstalk would be operative, even though Tg-neu tumors express a constitutively activated ErbB2 receptor. Indeed, overexpression of hypofunctional ErbB1 delays mammary tumor onset in MMTV-neuNDL mice, which express an oncogenic form of ErbB2 (46); the delayed latency of these tumors correlates with lower
phosphorylation of GAB1, an adapter protein involved in ERK signaling (47). It is tempting to speculate that CX3CL1-induced transactivation causes qualitative and quantitative changes in the strength, frequency and/or adaptation of ERK signaling in transformed mammary cells, conferring a proliferative advantage. Some studies indicate that these ERK signaling parameters affect cell fate decisions (16, 48).

In summary, we show that CX3CL1 acts as a tumor promoter for the development of spontaneous mouse mammary carcinomas, in models in which ErbB signaling is relevant for tumorigenesis. Our results also highlight the importance of the GPCR-RTK crosstalk in early stages of breast carcinogenesis, which might be extensible to other cancer types (49). Since the \textit{erbB2} gene is amplified in \textasciitilde30\% of human breast tumors, and \textasciitilde50\% of breast cancers overexpress EGFR and EGFRvIII receptors (15, 50), we propose that the CX3CL1-induced ErbB transactivation reported here operates in human breast cancers, the most common malignancy among women worldwide.
Acknowledgments

We thank T. Thomson, A. Zaballos and A. Pandiella for advice and discussion, M. Mellado for the Fc cassette vector, V. Bronte and A. Mantovani for N202.1A and 1G11 cell lines, respectively, M.C. Moreno for help with cell sorting, E. García for CX3CL1 analysis in human samples, and C. Mark for editorial assistance.

Grant support

This work was supported by the Spanish Ministry of Science and Innovation (SAF2011-24553), the Comunidad de Madrid (IMMUNOTHERCAN; S2010/BMD-2326) and Fundación La Caixa (to S Mañes).

The authors have no conflicting financial interests.

Author contributions

Conceived and designed experiments: MT, SM. Performed the experiments: MT, EM, AMF. Immunohistochemistry: MAG-C, IA. Provided reagents and discussed results: MQ-F and SAL. Data analysis: MT, EM, SM. Wrote the paper: MT, EM, SM. All authors revised and approved the manuscript.
References


Legends to the figures

Fig. 1. CX3CL1 is expressed in specific cell types in the mouse mammary gland. Analysis of cell types composing non-tumor mammary glands. A, FACS analysis of a representative purification experiment. B, Graph summarizing the percentage of each cell type; data are mean ± SEM in 3 independent experiments (n = 32 glands each). C-D, Relative expression of CX3CL1 (C) and CX3CR1 (D) mRNA in the cell subtypes. Data are mean ± SEM of the relative quantity ($2^{-\Delta\Delta Ct}$) using as reference the sample with the highest Ct value for each mRNA after normalization to β-actin (n = 3). n.d., not detected (Ct = 40).

Fig. 2. CX3CL1 is downmodulated in breast tumors compared to healthy breast tissue. A, Relative proportion of cell types in Tg-neu tumors; data are mean ± SEM (n = 6). B, Relative quantity of CX3CL1 mRNA in epithelial (CD24high) and endothelial cells isolated from tumors and normal breasts; data are mean ± SEM (n = 3, non-tumor; n = 6, tumors; Mann-Whitney test). C, CX3CL1 levels in total extracts from normal glands and breast tumors determined by ELISA (n = 28); each point is the mean of triplicates from at least two independent assays (2-tailed Student t-test). D, CX3CL1 protein amounts for paired non-tumor and tumor samples as in C. E, Relative quantity of CX3CR1 mRNA in the indicated cell types isolated from tumors and normal glands as in B. F, Relative expression of CX3CL1 and CX3CR1 mRNA in human breast tumors and normal tissue; data derived from GEOprofile Database. For B, E and F, data were compared using the Mann-Whitney U-test; normal breast tissue (blue), tumors (yellow). G, H, CX3CL1 staining of representative in situ (G) and invasive (H) human ductal carcinomas (n = 4); adjacent non-tumor breast tissue (a) is also indicated. Higher magnification insets are also shown. Fisher two-tailed test to compare tumor and normal tissue, p-value = 0.0286.

Fig. 3. CX3CL1 overexpression increases breast carcinogenesis in Tg-neu mice. A, Relative CX3CL1 mRNA expression in uninfected (NI), Ad-CX3CL1- and Ad-LacZ-infected
N202.1A cells (m.o.i. indicated). B, ELISA determination of CX3CL1 levels in extracts of N202.1A cells as in A; β-galactosidase activity in extracts of Ad-LacZ-infected cells is shown as control. C-D, ELISA determination of CX3CL1 levels in extracts (C) and conditioned medium (D) of Ad-CX3CL1- and Ad-LacZ-infected 1g11 cells. For A-D, data are mean ± SEM of triplicates in one representative experiment of two performed. E, CX3CL1 mRNA levels in cell populations isolated from Tg-neu tumors after intratumor Ad-CX3CL1 injection. F, CX3CL1 serum levels in mice as in (E); n = 3 mice/group. G, Tumor growth kinetics in Tg-neu mice after i.t. injections (arrows) of Ad-CX3CL1 or Ad-LacZ viruses. H,I, Hematoxylin/eosin-stained sections of formalin-fixed tumors inoculated with Ad-CX3CL1 or Ad-LacZ. Representative images are shown (n = 3 tumors/group). J, Mean tumor number in Tg-neu mice as in (G). For G and J, data are mean ± SEM (n = 5 mice/group; two-way ANOVA with Bonferroni post-test).

**Fig. 4. Detection of microtumors in Ad-CX3CL1-treated mice.** A, Panoramic view of hematoxylin/eosin-stained mammary glands without macroscopic tumors from an Ad-CX3CL1-injected mouse. Selected areas are shown at higher magnification in B (tumor mass), C (normal glands) and D (glands with intraductal epithelial proliferation). E, Some glands distant from the tumor showed characteristics similar to the hyperplastic foci described above.

**Fig. 5. CX3CL1 induces transactivation of the EGF pathway in tumors and breast epithelial cells.** A, [3H]-TdR incorporation in T47D cells, unstimulated (-) or stimulated with CX3CL1, with or without FCS and the indicated inhibitors. Data are mean ± SEM c.p.m. from triplicates in a representative experiment (n = 2 without FCS; n = 5 with FCS; one-way ANOVA, Dunnett post-test). B, CX3CL1-induced tyrosine phosphorylation of ErbB1 in T47D cells stimulated with the chemokine for the indicated times, alone or with AG1478. Cell extracts were precipitated with anti-phosphotyrosine (p-Tyr) antibody (top) or directly
resolved by SDS-PAGE and blotted with anti-ErbB1 (bottom); a representative experiment of two is shown. C, CX3CL1-induced Ca$^{2+}$ flux in vehicle- or PTx-treated T47D cells loaded with Fluo-3,AM ($n = 2$). D-E, Analysis of CX3CL1-induced ERK (D) and AKT (E) activation in T47D cells pretreated with inhibitors and stimulated with CX3CL1 for indicated times. Phosphorylated ERK 1/2 and AKT, and total ERK and AKT were determined in cell extracts. pERK/ERK (D) and pAKT/AKT (E) ratios were calculated by densitometry and normalized to unstimulated conditions. Data are mean $\pm$ SEM ($n = 4$; two-way ANOVA with Bonferroni post-test). F, Blockade of CX3CL1-induced ERK phosphorylation by neutralizing antibodies to the indicated ErbB ligands. Numbers (bottom) indicate the pERK/ERK ratio for each condition. G, H, Analysis of CX3CL1-induced ErbB2 phosphorylation in primary cultures of Tg-neu tumors (G) or mammary epithelial cells (H). Representative blots of CX3CL1-stimulated tumors or breast epithelial cells, alone or with GM6001 ($n = 2$, tumors; $n = 3$, normal epithelium). Numbers (bottom) indicate the pErbB2/ErbB2 ratio for each condition.

**Fig. 6. CX3CL1 deficiency specifically delays breast carcinogenesis in Tg-neu mice.** (A) Kaplan-Meier plots showing the percentage of tumor-free, virgin female Tg-neu ($n = 21$), Tg-neu-CX3CL1$^{+/−}$ ($n = 26$) and Tg-neu-CX3CL1$^{−/−}$ ($n = 20$) mice as a function of post-natal age (*$p = 0.04$; $$$p <0.0001$; Log-rank Test). (B) Number of palpable breast tumors per mouse (mean $\pm$ SEM) in Tg-neu ($n = 22$), Tg-neu-CX3CL1$^{+/−}$ ($n = 21$) and Tg-neu-CX3CL1$^{−/−}$ ($n = 8$) mice (*$p <0.05$; $$p <0.01$; two-way Anova with Bonferroni post-test). (C) Growth of spontaneous tumors in mice in A) was analyzed by weekly measurement for 5 weeks. (D) CX3CL1 deficiency does not delay breast carcinogenesis in Tg-PyMT mice. Kaplan-Meier plots showing the percentage of tumor-free, virgin female Tg-PyMT ($n = 24$), Tg-PyMT-CX3CL1$^{+/−}$ ($n = 32$) and Tg-PyMT-CX3CL1$^{−/−}$ ($n = 19$) mice as a function of post-natal age.
(E, F) Mean number of tumors per mice (E) and growth kinetics (F) of breast tumors that arose in mice in D). Data are mean ± SEM.

**Fig. 7. Model of CX3CL1-induced breast carcinogenesis in ErbB2 transgenic mice.** We propose that CX3CL1 is not involved in tumor initiation, which is probably mediated by ErbB2 mutagenesis. In this model, CX3CL1 would promote the progression of small or preneoplastic lesions in the mammary gland by enhancing ERK pathway activation through transactivation of the ErbB receptor family. Direct activation of this mitogenic pathway by PyMT would overcome the effect of CX3CL1 on breast tumorigenesis in Tg-PyMT mice. HB-EGF, heparin-binding EGF; AR, amphiregulin, MMP, metalloprotease; ADAM, a disintegrin and metalloprotease.
**Figure 1**

<table>
<thead>
<tr>
<th>CD24 Intensity</th>
<th>CX3CL1 mRNA (Rq)</th>
<th>CD24 Intensity</th>
<th>CX3CR1 mRNA (Rq)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD45+CD31+CD24low/-</td>
<td>0.2 ± 0.1</td>
<td>CD45+CD31+CD24low/-</td>
<td>0.1 ± 0.0</td>
</tr>
<tr>
<td>CD45+CD31+CD24med</td>
<td>2.3 ± 1.2</td>
<td>CD45+CD31+CD24med</td>
<td>n.d.</td>
</tr>
<tr>
<td>CD45+CD31+CD24high</td>
<td>4.5 ± 2.3</td>
<td>CD45+CD31+CD24high</td>
<td>n.d.</td>
</tr>
</tbody>
</table>

**B**

![Bar chart showing cell percentages for different CD45, CD31, and CD24 intensity groups.]

**C**

![Bar chart showing CX3CL1 mRNA levels for different CD45, CD31, and CD24 intensity groups.]

**D**

![Bar chart showing CX3CR1 mRNA levels for different CD45, CD31, and CD24 intensity groups.]

**Legend:**

- CD24 Intensity:
  - low/–
  - med
  - high

- CD45 Intensity:
  - +

- CD31 Intensity:
  - +
Figure 2

A

B

C

D

E

F

G

H

Tardáguila et al.
Figure 3

(A) CX3CL1 mRNA (Rq)

(B) CX3CL1 (ng/mg extract)

(C) CX3CL1 (ng/mg extract)

(D) CX3CL1 (ng/ml)

(E) CX3CL1 mRNA (Rq)

(F) CX3CL1 (ng/ml)

(G) β-GAL activity (U/mg extract)

(H) CD24+

(I) CD31+

(J) Tumors/mouse

Ad-LacZ

Ad-CX3CL1

0.5 mm

200 μm

50 μm

on April 5, 2017. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from cancerres.aacrjournals.org on April 5, 2017

Tardáguila et al.

Figure 3
Figure 6

A. Tumor-free mice (%)

B. Tumors/mouse

C. Tumor volume (cm$^3$)

D. Tumor-free mice (%)

E. Tumors/mouse

F. Tumor volume (cm$^3$)

Tg-neu-CX3CL1$^{-/-}$ ($t_{50} = 54.0$)***

Tg-neu ($t_{50} = 31.7$)

Tg-neu-CX3CL1$^{+/+}$ ($t_{50} = 35.4$)*

PyMT ($t_{50} = 6.3$)

PyMT-CX3CL1$^{+/+}$ ($t_{50} = 5.8$)

PyMT-CX3CL1$^{-/-}$ ($t_{50} = 5.8$)
Mutated ErbB2

CX3CL1

G

PTx

Ca^{2+}

flux

TRANSFORMATION

MMP/ADAM

ErbB ligands
(HB-EGF, AR, TGFα)

Non-mutated ErbB receptor

GM6001

PyMT Overexpression

ERK

PI3K

SURVIVAL

PROLIFERATION

Tardáguila et al.

Figure 7
CX3CL1 promotes breast cancer via transactivation of the EGF pathway

Manuel Tardaguila, Emilia Mira, Miguel A. Garcia-Cabezas, et al.

Cancer Res  Published OnlineFirst May 29, 2013.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-12-3828

Supplementary Material  Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2013/05/24/0008-5472.CAN-12-3828.DC1

Author Manuscript  Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.